Q2 2025 · 13F-HR
REGENERON PHARMACEUTICALS, INC. (REGN)holdings as filed
Filed 2025-08-01 · accession 0001104659-25-073115
$1.49B
Reported value
4
Positions
2025-06-30
Period end
The Brief · REGENERON PHARMACEUTICALS, INC. (REGN) · Q2 2025
AI · grounded in 13F
REGENERON PHARMACEUTICALS, INC. (REGN) established a new position in Alnylam Pharmaceuticals, Inc. ALNY valued at $1.45B. The fund also initiated a position in Intellia Therapeutics, Inc. NTLA worth $34.7M. Additional new holdings include Adicet Bio, Inc. TORCEUR and Adverum Biotechnologies, Inc. AVU0.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 02043Q107 | ALNY | Alnylam Pharmaceuticals, Inc. | $1.45B | 97.6% | 4,444,445 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $34.7M | 2.34% | 3,702,995 | Common | SOLE |
| 007002108 | TORCEUR | Adicet Bio, Inc. | $590,592 | 0.04% | 968,183 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $388,954 | 0.03% | 180,909 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.